This firm's average rating is Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on TransEnterix market sentiment investors' perception of the future value of TransEnterix. Let us look at a few aspects of TransEnterix technical analysis.
Analyzing Asensus Surgical competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Asensus Surgical across multiple sectors and
. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Closer look at TransEnterix Variance
TransEnterix has current Variance of 253.16. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.
Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.
Variance | = | SUM(RET DEV)2 N |
| = | 253.16 |
| SUM | = | Summation notation |
| RET DEV | = | Actual returns deviation over selected period |
| N | = | Number of points for the period |
Let's now compare TransEnterix Variance to its closest peers:
| TRXC | 253.16 |
| ABT | 1.75 |
| SYK | 3.4 |
| BIO | 6.57 |
| ZBH | 4.74 |
Another 3 percent rise for TransEnterix
Current skewness is at 3.4. As of the 23rd of January, TransEnterix has the Semi Deviation of 4.09,
risk adjusted performance of 0.2655, and Coefficient Of Variation of 377.69. In relation to
fundamental indicators, the
technical analysis model makes it possible for you to check existing technical drivers of TransEnterix, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We are able to interpolate and collect nineteen
technical drivers for TransEnterix, which can be compared to its competition. Please validate
TransEnterix variance, as well as the
relationship between the value at risk and
skewness to decide if TransEnterix is priced more or less accurately, providing market reflects its prevalent price of 3.71 per share. Given that TransEnterix has
jensen alpha of 4.15, we advise you to double-check TransEnterix's current market performance to make sure the company can sustain itself at a future point.
Our Final Perspective on TransEnterix
Whereas other companies under the medical devices industry are still a bit expensive, TransEnterix may offer a potential longer-term growth to investors. To conclude, as of the 23rd of January 2021, we believe that at this point, TransEnterix is abnormally volatile with
very low odds of financial turmoil within the next 2 years. From a slightly different point of view, the entity appears to be
overvalued. Our primary 30 days Buy-Hold-Sell recommendation on the company is
Hold.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Asensus Surgical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
